Criteria Used to Determine Platinum Eligibility in Patients with Metastatic Urothelial Carcinoma: Results of a Physician Survey in Five European Countries.

ABSTRACT:

Background and objective

Although, for decades, first-line treatment for metastatic urothelial carcinoma (mUC) has been based on eligibility for platinum-based chemotherapy (cisplatin or carboplatin), the platinum-ineligibility criteria used by European physicians in real-world practice are unclear. This study assessed the factors and clinical thresholds used by European physicians to determine platinum ineligibility and alignment with the published US thresholds.

Methods

Physicians in France, Germany, Italy, Spain, and the UK completed a quantitative online survey from August to September 2022. Physicians reported percentages of patients perceived as platinum eligible and factors considered when determining platinum ineligibility. A previous US-based survey was adapted to i

SUBMITTER: Gupta S 

PROVIDER: S-EPMC12495075 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature